MARKET

ZURA

ZURA

Zura Bio Limited
NASDAQ
4.830
+0.030
+0.63%
After Hours: 4.851 +0.021 +0.44% 18:38 01/06 EST
OPEN
4.720
PREV CLOSE
4.800
HIGH
4.950
LOW
4.572
VOLUME
741.68K
TURNOVER
--
52 WEEK HIGH
5.75
52 WEEK LOW
0.9700
MARKET CAP
314.06M
P/E (TTM)
-7.2241
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ZURA last week (1229-0102)?
Weekly Report · 1d ago
Zura Bio Ltd. Discloses Athanor Capital as 10% Beneficial Owner
Reuters · 4d ago
Zura Bio resets key agreements after internal review
TipRanks · 4d ago
ZURA BIO LTD - ON DEC 29, CO AND UNITS ENTERED INTO SEVERAL AGREEMENTS WHICH WERE DETERMINED TO BE MORE COMMERCIALLY ADVANTAGEOUS TO CO - SEC FILING
Reuters · 4d ago
ZURA BIO LTD - NEW AGREEMENTS TERMINATE PREVIOUS AGREEMENTS WITH CO AND UNITS - SEC FILING
Reuters · 4d ago
Zura Bio Issues 8.7 Million Shares to Athanor in Private Placement
Reuters · 4d ago
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 12/29/2025 17:33
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/29/2025 17:05
More
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Webull offers Zura Bio Ltd stock information, including NASDAQ: ZURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZURA stock methods without spending real money on the virtual paper trading platform.